Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting

World News: . []

Spectrum Pharmaceuticals Inc NasdaqGS SPPI a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology today announced that data from the Phase ...

More news and information about Spectrum Pharmaceuticals, Inc.

Published By:

Business Wire: 12:00 GMT Thursday 6th December 2018

Published: .

Search for other references to "spectrum" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us